Crossmark

Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations

Published Online: 2022-03-01

Published Print: 2022-05

Authors

Han, Chao

Ding, Xuan

Li, Mengmeng

Luo, Ningning

Qi, Yingxue

Wang, Chengwei https://orcid.org/0000-0001-9228-0174
License Information

Text and Data Mining valid from 2022-03-01

Version of Record valid from 2022-03-01
More Information

Article History

Received: 30 September 2021

Accepted: 15 November 2021

First Online: 1 March 2022

Declarations

:

: The authors have declared no conflicts of interest.

: This article does not contain any studies with human participants or animals performed by any of the authors.

: Informed consent was obtained from the patient.

Document is current